Institutional members access full text with Ovid®

Share this article on:

Drug Label Revisions for Two Psychiatric Drugs

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: November 2011 - Volume 111 - Issue 11 - p 23
doi: 10.1097/01.NAJ.0000407286.02007.96
Drug Watch
  • The daily dosage of the anti-depressant citalopram (Celexa) has now been limited to 40 mg because of potential dose-dependent QT prolongation and the risk of life-threatening arrhythmias.
  • The label for the atypical antipsychotic asenapine (Saphris) has been revised to warn of possibly serious allergic reactions, including anaphylaxis and angioedema.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2011 Lippincott Williams & Wilkins, Inc.